Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""multiple myeloma"" wg kryterium: Temat


Starter badań:

Tytuł:
Treatment with low-dose, single-agent belantamab mafodotin is safe and provides long-term responses in heavily pretreated multiple myeloma patients.
Autorzy:
Avivi I; Department of Haematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Shragai T; Department of Haematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Luttwak E; Department of Haematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Trestman S; Department of Haematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Cohen YC; Department of Haematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2024 Mar; Vol. 112 (3), pp. 367-370. Date of Electronic Publication: 2023 Oct 26.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Aged ; Retrospective Studies ; Dexamethasone ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Tytuł:
Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma.
Autorzy:
Lu Q; State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yang D; College of Veterinary Medicine, Shaanxi Center of Stem Cells Engineering and Technology, Northwest A&F University, Yangling, 712100, China.
Li H; State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zhu Z; State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zhang Z; State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Chen Y; State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yang N; State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Li J; State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Wang Z; State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Niu T; Department of Hematology, State Key Laboratory of Biotherapy and Cancer Center, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address: .
Tong A; State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address: .
Pokaż więcej
Źródło:
Cancer letters [Cancer Lett] 2024 Mar 31; Vol. 585, pp. 216660. Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/drug therapy
Multiple Myeloma*/genetics
Neoplasms*/pathology
Humans ; Mice ; Animals ; B-Cell Maturation Antigen ; CD47 Antigen/genetics ; Receptors, Immunologic/genetics ; T-Lymphocytes ; Antigens, Differentiation ; Phagocytosis
Czasopismo naukowe
Tytuł:
MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis.
Autorzy:
Wang X; Department of Hematology, Shengjing Hospital, China Medical University, Shenyang, China.; Center for Reproductive Medicine, Shengjing Hospital, China Medical University, Shenyang, China.
Shi Y; Department of Hematology, Daping Hospital, Chongqing, China.
Shi H; Shenshan Medical Center, Memorial Hospital of Sun Yat-Sen University, Shanwei, China.
Liu X; Department of Hematology, Shengjing Hospital, China Medical University, Shenyang, China.
Liao A; Department of Hematology, Shengjing Hospital, China Medical University, Shenyang, China.
Liu Z; Department of Hematology, Shengjing Hospital, China Medical University, Shenyang, China.
Orlowski RZ; Departments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .
Zhang R; Department of Hematology, The First Affiliated Hospital, China Medical University, Shenyang, China. .
Wang H; Department of Hematology, Shengjing Hospital, China Medical University, Shenyang, China. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Mar 05; Vol. 43 (1), pp. 68. Date of Electronic Publication: 2024 Mar 05.
Typ publikacji:
Journal Article
MeSH Terms:
Proteasome Inhibitors*/pharmacology
Multiple Myeloma*/drug therapy
Multiple Myeloma*/genetics
Humans ; Oncogenes ; Cytoplasm ; Antiviral Agents ; DNA ; DNA, Circular ; Kinesins ; Mucins
Czasopismo naukowe
Tytuł:
Bortezomib modulated the autophagy-lysosomal pathway in a TFEB-dependent manner in multiple myeloma.
Autorzy:
Zhang R; Department of Internal Medicine, Hebei Medical University, Shijiazhaung 050000, China.
Yang X; Department of Hematology, The Affiliated Hospital of Chengde Medical College, Chengde 067000, China.
Shi X; Department of Hematology, The Affiliated Hospital of Chengde Medical College, Chengde 067000, China.
Xing E; Department of central laboratory, The Affiliated Hospital of Chengde Medical College, Chengde 067000, China.
Wang L; Department of Hematology, The Affiliated Hospital of Chengde Medical College, Chengde 067000, China.
Hao C; Department of Internal Medicine, Hebei Medical University, Shijiazhaung 050000, China; Department of Hematology, The Affiliated Hospital of Chengde Medical College, Chengde 067000, China. Electronic address: .
Zhang Z; Department of Hematology, The Affiliated Hospital of Chengde Medical College, Chengde 067000, China. Electronic address: .
Pokaż więcej
Źródło:
Leukemia research [Leuk Res] 2024 Mar; Vol. 138, pp. 107455. Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/drug therapy
Multiple Myeloma*/genetics
Multiple Myeloma*/metabolism
Humans ; Bortezomib/pharmacology ; Autophagy ; Autophagosomes/metabolism ; Lysosomes/metabolism ; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/genetics
Czasopismo naukowe
Tytuł:
Oncolytic Myxoma virus Increases Autophagy in Multiple Myeloma
Autorzy:
Yeşilaltay A; Başkent University İstanbul Hospital, Department of Hematology, İstanbul, Türkiye
Muz D; Tekirdağ Namık Kemal University Faculty of Veterinary Medicine, Department of Virology, Tekirdağ, Türkiye
Erdal B; Tekirdağ Namık Kemal University Faculty of Medicine, Department of Microbiology, Tekirdağ, Türkiye
Pokaż więcej
Źródło:
Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2024 Mar 01; Vol. 41 (1), pp. 16-25. Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:
Journal Article
MeSH Terms:
Oncolytic Viruses*
Multiple Myeloma*/therapy
Multiple Myeloma*/pathology
Myxoma virus*/genetics
Animals ; Mice ; Humans ; Beclin-1/genetics ; Cell Line, Tumor ; Autophagy
Czasopismo naukowe
Tytuł:
Chromosomal defects in multiple myeloma.
Autorzy:
Clarke SE; School of Biomedical Sciences, The University of Western Australia (M504), Crawley, WA 6009, Australia; Department of Haematology, PathWest Laboratory Medicine WA, Fiona Stanley Hospital, Murdoch, WA 6150, Australia. Electronic address: .
Fuller KA; School of Biomedical Sciences, The University of Western Australia (M504), Crawley, WA 6009, Australia. Electronic address: .
Erber WN; School of Biomedical Sciences, The University of Western Australia (M504), Crawley, WA 6009, Australia; PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, WA 6000, Australia. Electronic address: .
Pokaż więcej
Źródło:
Blood reviews [Blood Rev] 2024 Mar; Vol. 64, pp. 101168. Date of Electronic Publication: 2024 Jan 04.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/genetics
Multiple Myeloma*/therapy
Humans ; Chromosome Aberrations ; Translocation, Genetic ; In Situ Hybridization, Fluorescence/methods ; Gene Rearrangement
Czasopismo naukowe
Tytuł:
Immunoglobulin Replacement Therapy for Hypogammaglobulinemia in Multiple Myeloma Should Not Be Ignored
Autorzy:
Zhang Q; Zhejiang Provincial People’s Hospital Bijie Hospital, Department of Cardiology, Bijie, China
Wang Y; Xinchang Hospital Affiliated to Wenzhou Medical University, Department of Thoracic Surgery, Xinchang, China
Pan W; Haiyan People’s Hospital, Department of Clinical Laboratory, Haiyan, China
Pokaż więcej
Źródło:
Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2024 Mar 01; Vol. 41 (1), pp. 51-52. Date of Electronic Publication: 2024 Jan 04.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/complications
Multiple Myeloma*/drug therapy
Agammaglobulinemia*/diagnosis
Agammaglobulinemia*/etiology
Agammaglobulinemia*/therapy
Humans ; Immunoglobulin G ; Immunization, Passive
Czasopismo naukowe
Tytuł:
Myelomatous meningitis diagnosed by cerebrospinal fluid cytology examination.
Autorzy:
Bizzarro T; Operative Unit of Pathologic Anatomy, AUSL della Romagna, 'M. Bufalini' Hospital, Cesena, Italy.
De Marco G; Department of Biomedical and NeuroMotor Sciences of Bologna, University of Bologna, Bologna, Italy.
Romoli M; Neurology and Stroke Unit, Department of Neuroscience, AUSL della Romagna, 'M. Bufalini' Hospital, Cesena, Italy.
Paolucci L; Operative Unit of Pathologic Anatomy, AUSL della Romagna, 'M. Bufalini' Hospital, Cesena, Italy.
Morigi F; Operative Unit of Pathologic Anatomy, AUSL della Romagna, 'M. Bufalini' Hospital, Cesena, Italy.
Longoni M; Neurology and Stroke Unit, Department of Neuroscience, AUSL della Romagna, 'M. Bufalini' Hospital, Cesena, Italy.
Bartolini D; Operative Unit of Pathologic Anatomy, AUSL della Romagna, 'M. Bufalini' Hospital, Cesena, Italy.
Pokaż więcej
Źródło:
Cytopathology : official journal of the British Society for Clinical Cytology [Cytopathology] 2024 Mar; Vol. 35 (2), pp. 307-309. Date of Electronic Publication: 2023 Oct 25.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/pathology
Meningitis*/diagnosis
Meningitis*/cerebrospinal fluid
Humans ; Cytological Techniques ; Cytodiagnosis
Czasopismo naukowe
Tytuł:
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
Autorzy:
Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
Ludwig H; Medical Department Center for Oncology, Hematology and Palliative Medicine, Wilhelminen Cancer Research Institute, Vienna, Austria.
Mateos MV; Institute of Cancer Molecular and Cellular Biology, University Hospital of Salamanca, Salamanca, Spain.
Larocca A; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy.
Abdulhaq H; Department of Hematology and Oncology, University of California, San Francisco, Fresno, California, USA.
Norin S; Clinical Science, Oncopeptides AB, Stockholm, Sweden.
Thuresson M; Biostatistics, Oncopeptides AB, Stockholm, Sweden.
Bakker NA; Clinical Science, Oncopeptides AB, Stockholm, Sweden.
Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2024 Mar; Vol. 112 (3), pp. 402-411. Date of Electronic Publication: 2023 Nov 15.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Hematopoietic Stem Cell Transplantation*
Melphalan/*analogs & derivatives
Phenylalanine/*analogs & derivatives
Thalidomide/*analogs & derivatives
Humans ; Melphalan/therapeutic use ; Alkylating Agents/therapeutic use ; Dexamethasone/adverse effects ; Transplantation, Autologous ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Tytuł:
Treatment sequences and drug costs from diagnosis to death in multiple myeloma.
Autorzy:
Seefat MR; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Cucchi DGJ; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
Groen K; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Donker ML; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
van der Hem KG; Department of Internal Medicine, Zaandam Medical Center, Zaandam, The Netherlands.
Westerman M; Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands.
Gerrits AM; Department of Internal Medicine, OLVG, Amsterdam, The Netherlands.
Beeker A; Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands.
van de Donk NWCJ; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Blommestein HM; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Zweegman S; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2024 Mar; Vol. 112 (3), pp. 360-366. Date of Electronic Publication: 2023 Oct 11.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Humans ; Drug Costs ; Retrospective Studies ; Health Care Costs ; Death ; Cost-Benefit Analysis
Czasopismo naukowe
Tytuł:
Teclistamab-cqyv in multiple myeloma.
Autorzy:
Martino EA; Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Bruzzese A; Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Labanca C; Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Mendicino F; Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Lucia E; Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Olivito V; Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Neri A; Scientific Directorate IRCCS of Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy.
Morabito F; Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy.
Vigna E; Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Gentile M; Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.; Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2024 Mar; Vol. 112 (3), pp. 320-327. Date of Electronic Publication: 2023 Oct 17.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Antineoplastic Agents*/therapeutic use
Antineoplastic Agents*/pharmacology
Humans ; B-Cell Maturation Antigen ; Neoplasm Recurrence, Local/drug therapy ; Proteasome Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
CD200 genotype is associated with clinical outcome of patients with multiple myeloma.
Autorzy:
Gonzalez-Montes Y; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Universitat de Girona, Girona, Spain.
Osca-Gelis G; Hospital Cancer Registry Unit, Catalan Institute of Oncology, Girona, Spain.; Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Girona, Spain.; Center CIBER of Epidemiology and Public Health (CIBERESP), Girona, Spain.
Rodriguez-Romanos R; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Universitat de Girona, Girona, Spain.
Villavicencio A; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Universitat de Girona, Girona, Spain.
González-Bártulos M; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Universitat de Girona, Girona, Spain.
Llopis F; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Universitat de Girona, Girona, Spain.
Clapes V; Clinical Hematology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Institut d'Investigaciò Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.
Oriol A; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Barcelona, Spain.
Sureda A; Clinical Hematology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Institut d'Investigaciò Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.
Escoda L; Hematology Department, Institut Català d'Oncologia, Hospital Joan XXIII, Universitat Rovira i Virgili (URV), Tarragona, Spain.
Sarrà J; Hematology Department, Institut Català d'Oncologia, Hospital Joan XXIII, Universitat Rovira i Virgili (URV), Tarragona, Spain.
Garzó A; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Universitat de Girona, Girona, Spain.
Lloveras N; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Universitat de Girona, Girona, Spain.
Gómez B; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Universitat de Girona, Girona, Spain.
Granada I; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Barcelona, Spain.
Gallardo D; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Universitat de Girona, Girona, Spain.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2024 Feb 22; Vol. 15, pp. 1252445. Date of Electronic Publication: 2024 Feb 22 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/genetics
Multiple Myeloma*/therapy
Multiple Myeloma*/diagnosis
Humans ; Immune System/metabolism ; Prognosis ; Retrospective Studies ; Stem Cell Transplantation
Czasopismo naukowe
Tytuł:
Oral health, dental treatment, and medication related osteonecrosis of the jaw in multiple myeloma - a longitudinal cohort study.
Autorzy:
Olofsson R; Specialist Clinic for Orofacial Medicine Uddevalla - Trollhättan, Public Dental Service, Region Västra Götaland, Uddevalla, Sweden. .; Department of Oral Microbiology and Immunology, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden. .
Korytowska M; Specialist Clinic for Orofacial Medicine, Karlstad, Public Dental Service, Region Värmland, Sweden.; Department of Oral Maxillofacial Surgery and Oral Medicine, Malmö University, Malmö, Sweden.
Almhöjd U; Department of Cariology, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Almståhl A; Department of Oral Microbiology and Immunology, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.; Section 4 - Oral health, Faculty of Odontology, Malmö University, Malmö, Sweden.
Cevik-Aras H; Specialist Clinic for Orofacial Medicine Uddevalla - Trollhättan, Public Dental Service, Region Västra Götaland, Uddevalla, Sweden.; Department of Oral Pathology and Medicine, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Pokaż więcej
Źródło:
BMC oral health [BMC Oral Health] 2024 Feb 05; Vol. 24 (1), pp. 184. Date of Electronic Publication: 2024 Feb 05.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/drug therapy
Multiple Myeloma*/chemically induced
Multiple Myeloma*/complications
Bone Density Conservation Agents*/adverse effects
Osteonecrosis*/chemically induced
Osteonecrosis*/prevention & control
Humans ; Oral Health ; Longitudinal Studies ; Retrospective Studies ; Quality of Life ; Diphosphonates/adverse effects ; Dental Care
Czasopismo naukowe
Tytuł:
The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study.
Autorzy:
Emery A; Department for Health, University of Bath, Bath, UK.
Moore S; Department for Haematology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.
Crowe J; Department for Haematology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.
Murray J; Department for Haematology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.
Peacock O; Department for Health, University of Bath, Bath, UK.
Thompson D; Department for Health, University of Bath, Bath, UK.
Betts F; Department for Health, University of Bath, Bath, UK.
Rapps S; Department for Health, University of Bath, Bath, UK.
Ross L; Department for Health, University of Bath, Bath, UK.
Rothschild-Rodriguez D; School of Biological Sciences, University of Southampton, Southampton, UK.
Arana Echarri A; Department for Health, University of Bath, Bath, UK.
Davies R; Department for Health, University of Bath, Bath, UK.
Lewis R; Department for Physiotherapy, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.
Augustine DX; Department for Health, University of Bath, Bath, UK.; Department for Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.
Whiteway A; Department for Haematology, North Bristol NHS Trust, Bristol, UK.
Afzal Z; Clinical Immunology Service, Institute of Immunity and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Heaney J; Clinical Immunology Service, Institute of Immunity and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Drayson MT; Clinical Immunology Service, Institute of Immunity and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Turner JE; Department for Health, University of Bath, Bath, UK.; School of Sport, Exercise and Rehabilitation Sciences, College of Life and Environmental Sciences, University of Birmingham, Edgbaston, Birmingham, UK.
Campbell JP; Department for Health, University of Bath, Bath, UK. .; School of Medical and Health Sciences, Edith Cowan University, WA, Joondalup, Australia. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 05; Vol. 24 (1), pp. 174. Date of Electronic Publication: 2024 Feb 05.
Typ publikacji:
Journal Article
MeSH Terms:
Monoclonal Gammopathy of Undetermined Significance*/therapy
Monoclonal Gammopathy of Undetermined Significance*/diagnosis
Multiple Myeloma*/diagnosis
Paraproteinemias*
Smoldering Multiple Myeloma*
Humans ; Adult ; Pilot Projects ; Quality of Life ; Disease Progression ; Biomarkers ; Exercise
Czasopismo naukowe
Tytuł:
Treatment Pattern and Outcome of Newly Diagnosed Multiple Myeloma Patients in a Resource-Limited Setting.
Autorzy:
Cheong CS; Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Tengku K Aziz TAH; Beacon Hospital, Petaling Jaya, Selangor, Malaysia.
Anuar NA; KPJ Ampang Puteri Specialist Hospital, Ampang, Selangor, Malaysia.
Bee PC; Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Chin EFM; Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Khairullah S; Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Liong CC; Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Zamri Y; Universiti Malaya Medical Center, Kuala Lumpur, Malaysia.
Gan GG; Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Pokaż więcej
Źródło:
Asian Pacific journal of cancer prevention : APJCP [Asian Pac J Cancer Prev] 2024 Feb 01; Vol. 25 (2), pp. 595-601. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/therapy
Hematopoietic Stem Cell Transplantation*
Humans ; Adult ; Middle Aged ; Aged ; Aged, 80 and over ; Bortezomib/therapeutic use ; Retrospective Studies ; Resource-Limited Settings ; Dexamethasone ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Transplantation, Autologous ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Racial differences in treatment and survival among older patients with multiple myeloma.
Autorzy:
Wang R; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, Connecticut, USA.
Neparidze N; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, Connecticut, USA.; Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, Connecticut, USA.
Ma X; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, Connecticut, USA.
Colditz GA; Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.
Chang SH; Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.
Wang SY; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, Connecticut, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (3), pp. e6915. Date of Electronic Publication: 2024 Jan 17.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/drug therapy
Multiple Myeloma*/mortality
Healthcare Disparities*
Aged ; Humans ; Black or African American ; Databases, Factual ; Medicare ; Race Factors ; United States/epidemiology
Czasopismo naukowe
Tytuł:
Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters.
Autorzy:
Gupta L; Former Junior Resident, MD Pathology, Department of Hematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Suku P; Junior Research Fellow, Department of Hematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Dash A; PhD Scholar, Department of Hematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Bose P; Senior Lab Technician, Department of Hematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Sharma P; Assistant Professor, Department of Hematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Mallik N; Assistant Professor, Department of Hematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Sreedharanunni S; Associate Professor, Department of Hematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Varma N; Former Professor & Head, Department of Hematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Jandial A; Former Senior Research Associate, Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Malhotra P; Professor and Head, Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Sachdeva MUS; Professor, Department of Hematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Electronic address: .
Pokaż więcej
Źródło:
Current problems in cancer [Curr Probl Cancer] 2024 Feb; Vol. 48, pp. 101025. Date of Electronic Publication: 2023 Nov 10.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/therapy
Multiple Myeloma*/drug therapy
Hypoalbuminemia*/metabolism
Hypoalbuminemia*/pathology
Plasmacytoma*/pathology
Thrombocytopenia*/metabolism
Thrombocytopenia*/pathology
Humans ; Female ; Plasma Cells/metabolism ; Plasma Cells/pathology ; Prognosis
Czasopismo naukowe
Tytuł:
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma.
Autorzy:
Garcia JB; Hematology and BMT Unit, 'Azienda Ospedaliero-Universitaria di Parma', Parma.
Storti P; Department of Medicine and Surgery, University of Parma, Parma.
Iannozzi NT; Department of Medicine and Surgery, University of Parma, Parma.
Marchica V; Department of Medicine and Surgery, University of Parma, Parma.
Agnelli L; Istituto Nazionale dei Tumori Foundation, Milan.
Toscani D; Department of Medicine and Surgery, University of Parma, Parma.
Franceschi V; Department of Medical-Veterinary Science, University of Parma, Parma.
Todaro G; Hematology and BMT Unit, 'Azienda Ospedaliero-Universitaria di Parma', Parma.
Sammarelli G; Hematology and BMT Unit, 'Azienda Ospedaliero-Universitaria di Parma', Parma.
Notarfranchi L; Department of Medicine and Surgery, University of Parma, Parma.
Scita M; Hematology and BMT Unit, 'Azienda Ospedaliero-Universitaria di Parma', Parma.
Palma BD; Hematology and BMT Unit, 'Azienda Ospedaliero-Universitaria di Parma', Parma.
Raimondi V; Department of Medicine and Surgery, University of Parma, Parma.
Lungu O; Department of Medicine and Surgery, University of Parma, Parma.
Pruneri G; Istituto Nazionale dei Tumori Foundation, Milan.
Donofrio G; Department of Medical-Veterinary Science, University of Parma, Parma.
Giuliani N; Hematology and BMT Unit, 'Azienda Ospedaliero-Universitaria di Parma', Parma, Italy; Department of Medicine and Surgery, University of Parma, Parma. .
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2024 Feb 01; Vol. 109 (2), pp. 627-631. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/genetics
Smoldering Multiple Myeloma*
Humans ; Chromosome Aberrations ; Gene Amplification ; RNA-Binding Proteins/genetics ; Proteasome Endopeptidase Complex/metabolism
Czasopismo naukowe
Tytuł:
Outcome of Multiple Myeloma Patients With Hepatitis B Surface Antigen: Korean Multiple Myeloma Working Party 2103 Study.
Autorzy:
Yi JH; Division of Hematology-Oncology, Department of Medicine, Chung-Ang University, Seoul, Korea.
Lee JL; Department of Hemato-oncology, Daegu Fatima Hospital, Daegu, Korea.
Lee YJ; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Kang HJ; Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Park YH; Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.
Yuh YJ; Department of Internal Medicine, Sanggye-Paik Hospital, Inje University, Seoul, Korea.
Lim SN; Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
Kim HJ; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
Jung SH; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital and Chonnam National University Medical School, Hwasun-gun, Jeollanam-do, Korea.
Lee JJ; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital and Chonnam National University Medical School, Hwasun-gun, Jeollanam-do, Korea.
Cho HJ; Department of Hematology-Oncology, Kyungpook National University Hospital, Kyungpook National University, Daegu, Korea.
Moon JH; Department of Hematology-Oncology, Kyungpook National University Hospital, Kyungpook National University, Daegu, Korea.
Yhim HY; Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Korea.
Kim K; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: .
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Feb; Vol. 24 (2), pp. e50-e57.e2. Date of Electronic Publication: 2023 Oct 14.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Multiple Myeloma*/complications
Multiple Myeloma*/therapy
Hepatitis B*/complications
Hepatitis B*/drug therapy
Humans ; Male ; Middle Aged ; Female ; Hepatitis B Surface Antigens/pharmacology ; Hepatitis B Surface Antigens/therapeutic use ; Retrospective Studies ; Antiviral Agents/therapeutic use ; Virus Activation ; Hepatitis B virus ; Republic of Korea/epidemiology
Czasopismo naukowe
Tytuł:
B-cell maturation antigen chimeric antigen receptor-T therapy alleviated heart failure in patients with multiple myeloma.
Autorzy:
Wang Y; Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhang K; Department of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Suo X; Department of Hematology, Handan Central Hospital, Handan, China.
Meng N; School of Biological Science and Technology University of Jinan, Jinan, China.
Gu Y; Department of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Qin Y; Department of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Tu Y; Department of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhang X; Department of Hematology, Handan Central Hospital, Handan, China.
Sun G; Department of Hematology, Handan Central Hospital, Handan, China.
Ji J; Department of Hematology, Handan Central Hospital, Handan, China.
Wu W; Department of Echocardiography, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Cai Y; Department of Echocardiography, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yang K; Department of Magnetic Resonance Imaging, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ouyang C; Department of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Qi J; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Pokaż więcej
Źródło:
ESC heart failure [ESC Heart Fail] 2024 Feb; Vol. 11 (1), pp. 574-580. Date of Electronic Publication: 2023 Nov 01.
Typ publikacji:
Case Reports
MeSH Terms:
Multiple Myeloma*/therapy
Multiple Myeloma*/drug therapy
Receptors, Chimeric Antigen*/therapeutic use
Heart Failure*/therapy
Heart Failure*/drug therapy
Male ; Humans ; B-Cell Maturation Antigen/therapeutic use ; Natriuretic Peptide, Brain ; Neoplasm Recurrence, Local/drug therapy
Raport

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies